Skip to main content
Date
Min
Max
Filter By
Home
Toggle Menu
Main navigation
Professionals
Services
Patent Prosecution
Utility Patents
Design Patents
Business Methods
Litigation
Appellate
District Court Litigation
ITC Litigation
Patent Forensics
Pharmaceutical Litigation
Trade Secrets
Post Grant Proceedings
Interferences
PTAB Trials
Patent Oppositions
Reexamination and Supplemental Examination
Reissue
PTAB Legal Experience and Advancement Program (LEAP)
Trademark & Brand Protection
Trademark Prosecution
Anti-Counterfeiting
Marketing & Advertising
Opinions & Advice
Opinions of Counsel
Due Diligence & IP Valuation
Licensing
Industries
Electronics & High Tech
Electronics
Communications
Software
Standard Essential Patents (SEPs)
Blockchain and Fintech
Artificial Intelligence (AI)
Nanotechnology
3-D Printing
Biotechnology
Biopharmaceuticals
Biosimilars
Therapeutic Antibodies
Industrial & Agricultural Biotech
Pharmaceuticals
Prescription & OTC Drugs
Infectious Diseases
Generic Drug Development
Chemical & Industrial
Industrial Products
Chemical Products
Consumer Goods & Services
Consumer Products
Food Science & Packaging
Internet
Healthcare & Medical Devices
Cannabis Patents and Trademarks
Digital Healthcare
Animal Health
Medical Devices
IP Protection of Data
About
Clients
Case Studies
Awards & Recognition
Diversity & Inclusion
Our Culture
History
Office
Pro Bono
Community Engagement
In Memoriam
Contact
Careers
Lawyers, Agents & Scientists
Summer Associates
Staff
News & Insights
News
Publications
Events
Client Alerts
Newsletters
Multimedia
Subscribe
Search
Breadcrumb
Home
News & Insights
Client Alerts
Federal Circuit Grants Injunction Keeping Sandoz’s Biosimilar Version of Neupogen Off Market Until Appeal Decided
May 7, 2015
Download PDF
126.15 KB
Author(s)
Paul A. Calvo, Ph.D.
Timothy "Tim" J. Shea, Jr.
